Get the Stockscreener App
12.63
5.04%
-0.67
After Hours:
12.65
0.02
+0.16%
Novavax Inc stock is traded at $12.63, with a volume of 4.11M.
It is down -5.04% in the last 24 hours and up +2.02% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$13.30
Open:
$13.21
24h Volume:
4.11M
Relative Volume:
0.64
Market Cap:
$2.03B
Revenue:
$793.74M
Net Income/Loss:
$-398.71M
P/E Ratio:
-1.7397
EPS:
-7.26
Net Cash Flow:
$-514.43M
1W Performance:
-1.33%
1M Performance:
+2.02%
6M Performance:
+164.23%
1Y Performance:
+74.45%
1-Day Range:
$12.62
$13.45
1-Week Range:
$11.90
$14.17
52-Week Range:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NASDAQ:NVAX) Trading Up 6.7% - MarketBeat
Vaccines Market Anticipates Remarkable Growth from 2024 to 2031 - openPR
John Jacobs is working to refocus Novavax for a new eraWashington Business Journal - The Business Journals
Novavax taps J&J, Merck alum as new R&D head - The Business Journals
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development - BioSpace
(NVAX) Trading Signals - Stock Traders Daily
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Noteworthy Wednesday Option Activity: ACN, NVAX, GIII - Nasdaq
Novavax Names Dr. Ruxandra Draghia-Akli as Executive Vice President and Head of Research & Development - citybiz
Novavax (NASDAQ:NVAX) Shares Gap Up to $13.29 - MarketBeat
Possible Bearish Signals With Novavax Insiders Disposing Stock - Simply Wall St
Novavax appoints new EVP of Research & Development - Investing.com
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax appoints new EVP of Research & Development By Investing.com - Investing.com UK
Novavax taps J&J, Merck alum as new R&D head - Washington Business Journal
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development - StockTitan
Profund Advisors LLC Cuts Position in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
On the hunt for Novavax: Why people are seeking out the 'traditional' COVID vaccine - Yahoo Life
Farallon Capital Management LLC Sells 753,750 Shares of Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab - Zacks Investment Research
Novavax surges as Sanofi COVID vaccine deal boosts outlook - MSN
Moderna's updated COVID-19 vaccine is coming to Alberta, but Novavax shots are not - CBC.ca
Renaissance Technologies LLC Makes New Investment in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
FDA approves updated Novavax COVID vaccine amid summer surge - MSN
Novavax (NASDAQ:NVAX) Shares Up 5.4% - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Shares Sold by E Fund Management Co. Ltd. - MarketBeat
Health Canada approves Novavax's updated COVID-19 vaccine for fall - CBC News
Health Canada approves updated Novavax COVID-19 vaccine - MSN
Novavax Inc. stock outperforms competitors despite losses on the day - MarketWatch
Health Canada approves updated Novavax COVID-19 vaccine - Global News Toronto
Health Canada approves updated Novavax COVID-19 vaccine - CP24
Health Canada approves updated Novavax COVID-19 vaccine - The Globe and Mail
Health Canada approves updated Novavax COVID-19 vaccine - Montreal Gazette
Health Canada approves updated Novavax COVID-19 vaccine - CTV News
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell? - Investor's Business Daily
Rhumbline Advisers Purchases 56,324 Shares of Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
An analyst sees good growth prospects for Novavax, Inc. (NVAX) - SETE News
Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest Position - MarketBeat
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
The new COVID vaccines are finally available. Here’s where you can get one in NC - Charlotte Observer
Ratios Revealed: Decoding Novavax, Inc. (NVAX)’s Financial Health - The Dwinnex
Why Novavax is Gaining Ground in COVID-19 Vaccine Race - Yahoo Finance
Why Novavax is Gaining Ground in COVID-19 Vaccine Race - Zacks Investment Research
Navigating NVAX Stock: Novavax, Inc. Journey - The InvestChronicle
Novavax announces availability of Covid-19 vaccine in US pharmacies - Pharmaceutical Business Review
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. - BioSpace
Novavax vaccine unavailable at UHS - Campus Times
Novavax COVID-19 vaccines now available - MSN
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):